Republished: Immune checkpoint inhibitor induced large vessel vasculitis
Daisy Henderson(Royal Free London NHS Foundation Trust), Debra H. Josephs(Guy's and St Thomas' NHS Foundation Trust), Mark Linch(London Cancer), Bihani Kularatne(University College London Hospitals NHS Foundation Trust), Robert H. Jones(Velindre NHS Trust), Simon J. Crabb(University of Southampton), Gelareh Eslamian(Guy's and St Thomas' NHS Foundation Trust), Peter Sankey(Royal Devon & Exeter NHS Foundation Trust), Daniel Poon(Rapt Therapeutics (United States))
Cited by 2
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2011|877
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|643
Attitudes and perceptions of UK medical students towards artificial intelligence and radiology: a multicentre survey
|Insights into Imaging|2020|492